MAB Stock Overview
A biotechnology company, engages in the development of various biotech drugs based on monoclonal antibody technology in Poland. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 0/6 |
| Past Performance | 1/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
+ 1 more risk
My Notes
Capture your thoughts, links and company narrative
Mabion S.A. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | zł9.01 |
| 52 Week High | zł21.18 |
| 52 Week Low | zł8.93 |
| Beta | 1.12 |
| 1 Month Change | -11.67% |
| 3 Month Change | -46.24% |
| 1 Year Change | -50.17% |
| 3 Year Change | -85.47% |
| 5 Year Change | -87.77% |
| Change since IPO | -33.16% |
Recent News & Updates
Some May Be Optimistic About Mabion's (WSE:MAB) Earnings
Nov 06
Investors Don't See Light At End Of Mabion S.A.'s (WSE:MAB) Tunnel And Push Stock Down 30%
Nov 05Recent updates
Some May Be Optimistic About Mabion's (WSE:MAB) Earnings
Nov 06Investors Don't See Light At End Of Mabion S.A.'s (WSE:MAB) Tunnel And Push Stock Down 30%
Nov 05Mabion's (WSE:MAB) Shareholders May Want To Dig Deeper Than Statutory Profit
Apr 24Mabion S.A. (WSE:MAB) Shares Fly 30% But Investors Aren't Buying For Growth
Nov 28Industry Analysts Just Made A Huge Upgrade To Their Mabion S.A. (WSE:MAB) Revenue Forecasts
Jun 02Does Mabion (WSE:MAB) Have A Healthy Balance Sheet?
Jul 09Mabion (WSE:MAB) Is Posting Solid Earnings, But It Is Not All Good News
Jun 04Is Mabion (WSE:MAB) Using Too Much Debt?
Dec 22Mabion S.A. (WSE:MAB) Shares Could Be 47% Below Their Intrinsic Value Estimate
Sep 11How Much Of Mabion S.A. (WSE:MAB) Do Institutions Own?
Feb 24Shareholder Returns
| MAB | PL Biotechs | PL Market | |
|---|---|---|---|
| 7D | -10.6% | -1.4% | -2.0% |
| 1Y | -50.2% | -24.8% | -4.3% |
Return vs Industry: MAB underperformed the Polish Biotechs industry which returned -24.7% over the past year.
Return vs Market: MAB underperformed the Polish Market which returned -4.5% over the past year.
Price Volatility
| MAB volatility | |
|---|---|
| MAB Average Weekly Movement | 6.9% |
| Biotechs Industry Average Movement | 6.0% |
| Market Average Movement | 4.9% |
| 10% most volatile stocks in PL Market | 8.6% |
| 10% least volatile stocks in PL Market | 3.2% |
Stable Share Price: MAB's share price has been volatile over the past 3 months compared to the Polish market.
Volatility Over Time: MAB's weekly volatility (7%) has been stable over the past year, but is still higher than 75% of Polish stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2007 | 244 | Krzysztof Kaczmarczyk | www.mabion.eu |
Mabion S.A., a biotechnology company, engages in the development of various biotech drugs based on monoclonal antibody technology in Poland. The company develops, produces, and sells medicines for the treatment of neoplastic, autoimmune, metabolic, and neurological diseases. Its products include MabionCD20 and MabionHER2.
Mabion S.A. Fundamentals Summary
| MAB fundamental statistics | |
|---|---|
| Market cap | zł145.62m |
| Earnings (TTM) | zł10.24m |
| Revenue (TTM) | zł110.79m |
14.2x
P/E Ratio1.3x
P/S RatioIs MAB overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| MAB income statement (TTM) | |
|---|---|
| Revenue | zł110.79m |
| Cost of Revenue | zł24.05m |
| Gross Profit | zł86.74m |
| Other Expenses | zł76.50m |
| Earnings | zł10.24m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.63 |
| Gross Margin | 78.29% |
| Net Profit Margin | 9.24% |
| Debt/Equity Ratio | 0.2% |
How did MAB perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/19 11:19 |
| End of Day Share Price | 2024/12/19 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Mabion S.A. is covered by 11 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Kamil Kliszcz | Biuro maklerskie mBanku |
| Beata Szparaga-Wasniewska | Biuro maklerskie mBanku |
| Pawel Sugalski | ING Groep NV |